AstraZeneca’s (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by equities researchers at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, Digital Look reports. They presently have a £117 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential downside of 1.43% from the company’s current price.

Several other brokerages have also weighed in on AZN. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Wednesday, September 9th. Citigroup lifted their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Berenberg Bank dropped their price objective on AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of £150.

AstraZeneca Trading Down 1.3%

LON AZN opened at £118.70 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 1-year low of £114.04 and a 1-year high of £157.32. The firm’s fifty day simple moving average is £121.34 and its 200-day simple moving average is £132.75. The company has a market capitalization of £184.09 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20.

Insider Activity at AstraZeneca

In related news, insider Michel Demare acquired 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of £121.21 per share, with a total value of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.